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Background:  Pulmonary arterial hypertension (PAH) is a rapidly progressive disorder with high mortality rates despite traditional medical 
treatment. With the availability of PA targeted therapy, early PAH detection improves treatment outcomes. Exercise- induced Pulmonary Artery 
Hypertension (EiPAH) represents an early phase of PAH in which Screening and early detection might facilitate treatment aimed at preventing 
progression of EiPAH to resting PAH. In this study we sought to determine change in 6 Minute Walk Distance (6MWD) after initiation of PA targeted 
therapy in EiPAH patients
methods:  Prior to the initiation of PA targeted therapy (Phosphodiesterase-5 Inhibitors PDE-5 or Endothelial Receptor Antagonists or Both),6MWD 
was measured at baseline in consecutive patients with EiPAH (mPAP less than 25 and PCWP less than 15 at rest, on exercise mPAP greater than 30 
and PCWP less than 15 and trans pulmonary gradient greater than 15mm of Hg). Patients were then started on PA targeted therapy and 6MWD was 
measured at 6 months.
results:  Patients with EiPAH (n=26) had resting mPAP of 20±3, on exercise mPAP = 37.2±5 mmHg, TPG=27±7 and mean 6mwd of 341±86 meters. 
After 6months of PA targeted therapy with PDE-5 inhibitors or ERAs or both, the repeat mean 6mwd was significantly higher (371±82, p=0.001,mean 
difference 30±42; Figure 1)
conclusion:  EiPAH on PA targeted therapy had a significant improvement at 6 months as evidenced by their increase in 6MWD and larger studies 
has to be performed to validate this hypothesis.
 
